Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis
Key result
Colchicine significantly reduced the risk of pericarditis during follow-up for primary or secondary prevention (RR 0.40; 95% CI 0.30 to 0.54; P<0.001).
Why the study?
Does colchicine prevent pericarditis in patients requiring primary or secondary prevention?
Population
795 patients from 5 controlled clinical trials focused on pharmacologic primary or secondary prevention of…
Comparison
Colchicine vs Placebo
Design
Meta-analysis, Randomized controlled trials, 3 double-blind, 2 open-label
Follow-up
mean 13 months
Authors
Discussion
Loading...
Member takes
Implication
Supports colchicine for pericarditis prevention in practice; confirms efficacy and safety across RCTs.
Study Design
Type
Meta-Analysis (n=795)
Structured PICO
Does colchicine prevent pericarditis in patients requiring primary or secondary prevention?
P
Population
795 patients from 5 controlled clinical trials evaluating colchicine for primary or secondary prevention of pericarditis, followed for a mean of 13 months.
I
Intervention
Colchicine
C
Comparator
Placebo
O
Outcome
Risk of pericarditis during follow-uphard clinical
Main Result
Relative Risk: 0.4 (95% CI 0.3–0.54)
p-value: p=<0.001
Colchicine significantly reduces the risk of pericarditis in both primary and secondary prevention settings without increasing severe adverse events.
Cite This Study
Imazio et al. (2012) conducted a meta-analysis in pericarditis (n=795). Colchicine vs. placebo was evaluated on pericarditis during follow-up (RR 0.40, 95% CI 0.30 to 0.54, p=<0.001). Colchicine significantly reduced the risk of pericarditis during follow-up for primary or secondary prevention (RR 0.40; 95% CI 0.30 to 0.54; P<0.001).